US2878160A - Tablet molding process - Google Patents

Tablet molding process Download PDF

Info

Publication number
US2878160A
US2878160A US556416A US55641655A US2878160A US 2878160 A US2878160 A US 2878160A US 556416 A US556416 A US 556416A US 55641655 A US55641655 A US 55641655A US 2878160 A US2878160 A US 2878160A
Authority
US
United States
Prior art keywords
nodules
granules
tablet
approximately
tablets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US556416A
Inventor
Smedresman Max
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NYSCO LAB Inc
NYSCO LABORATORIES Inc
Original Assignee
NYSCO LAB Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NYSCO LAB Inc filed Critical NYSCO LAB Inc
Priority to US556416A priority Critical patent/US2878160A/en
Application granted granted Critical
Publication of US2878160A publication Critical patent/US2878160A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Definitions

  • the various ingredients in intimately admixed powder form, are subjected to high pressures to produce large slugs of the material as a cohered solid mass. These slugs are then milled into granules of the desired size and configuration, the granules being thereafter recompressed in the conventional tablet-forming equipment to produce the finished product.
  • the slugging process is generally employed where the tablet ingredients may not be wetted due to some incompatibility or where they are heatsensitive and unstable. It is an expensive process which involves considerable labor and equipment and its application is limited and not always satisfactory.
  • the more common method is the wet granulating process.
  • the wetting agent generally consists of water, alcohol or other organic solvent with or without water, gum or other binder solutions, for example, acacia, tragacanth, methyl cellulose, gelatin, gelatinized starch, etc.
  • the tablet ingredients, wetted as above, to the proper consistency are placed in a suitable drying oven.
  • the dried solid cohered mass is then milled into granules of the required size, admixed with a suitable lubricant and formed into tablets as in the case of the slugging process.
  • the wet granulating process is likewise expensive, requiring considerable labor. Moreover, where organic solvents are employed, these are evaporated and seldom recovered, thus adding to the production costs.
  • the Wet granulating process cannot be used when the tablet ingredients are incompatible to wetting or are heat-sensitive.
  • Another object of the present invention is to provide an improved process for the manufacture of pills, tablets and the like.
  • Still another object of the present invention is to provide an improved method of producing pharmaceutical pills, tablets and the like.
  • a further object of the present invention is to provide an improved tablet producing method characterized by the absence of any slugging or wetting steps.
  • Still a further object of the present invention is to provide an improved tablet producing method which may be employed with materials sensitive to heat and wetting.
  • Another object of the present invention is to provide an improved inexpensive and versatile tablet producing process characterized by its low labor, material and equipment requirements and the use of standard apparatus.
  • a pharmaceutical pill, tablet or the like is produced by admixing a physiologically active ingredient in a finely divided state with a molten, preferably water soluble binder, solidifying the resultant mixture, comminuting the solidified mixture into granules and form: ing said granules into tablets.
  • the active ingredients and any desired excipients such as powdered sugar, milk sugar, starch, etc. in a powdered intimately admixed state, are placed in a conventional mixer such as a pony mixer, change. can mixer, tumbler mixer, or any other suitable mixer.
  • a conventional mixer such as a pony mixer, change. can mixer, tumbler mixer, or any other suitable mixer.
  • the mixer is actuated and the molten binder is slowly added during the continued mixing at a rate to efiect.
  • a suitable lubricant such as talc,- magnesium stearate, stearic acid or dry starch is added; For example, 2% to 3% magnesium stearate and 4%; to 1% talc based on the final weight of the tablets may be advantageously employed.
  • the balls or nodules are preferably of the order of about /a inch in diameter and, in any event, larger than about a 20 mesh.
  • the balls or nodules together with the lubricant are then granulated in any well known fashion, such as by means of a Fitzpatrick comminuter, to produce granules of between 20 to 60 mesh depending upon the size of the tablet to be produced. The granules are then formed into :tablets in the usual manner.
  • the binding material employed in forming the granules should preferably be Water soluble and should have a low melting point compatible with the other ingredients entering into the tablet so as not to adversely affect or decompose these ingredients and the melting point should not be too high for convenient handling. Binders having melting points below 120 C. are generally satisfactory, although this temperature may vary depending upon the other constituents. It is also preferable that the binder be colorless or white and not char or otherwise become discolored upon melting. Sorbitol has been found to excellently serve the function of the binder. It has a melting point of C. and is of a syrupy consistency or viscosity.
  • the binder is from 10% to 15% by weight of the final mixture and is added to the other ingredients during the mixing or tumbling thereof at a rate preferably not exceeding 20 percent of the molten binder per minute, for example, 10 percent per minute.
  • An example of the present improved process is in the production of phenobarbital tablets having a running weight of 1.3 grains and each containing gram phenobarbital.
  • the ingredients and quantities employed in the production of 1,050,000 of these tablets are as follows:
  • constituents may be varied approximately 10%.
  • spherical nodules small roughly spherical nodules of about Ms inch diameter.
  • the batch of lubricated nodules are then passed through a properly adjusted Fitzpatrick comminuter where the nodules are broken in granules of about 30 mesh. These granules are then formed into tablets in the usual and conventional manner.
  • the improved method of producing pills comprising the steps of slowly adding molten sorbitol to a finely divided active ingredient while agitating said active ingredient to produce nodules of the order of approximately diameter of said sorbitol and said active ingredient,

Description

United States Patent 2,878,160 TABLET MOLDING PROCESS Max Smedresman, Long Island City, N. Y., assignor to Nysco Laboratories, Inc., Long Island City, N. Y., a
corporation of New York No Drawing. Application December 30, 1955 Serial No. 556,416
4 Claims. (Cl. 167-82) a coherent mass of the shape of the finished tablet. The
common methods of producing the granules of suitable size and configuration are the so-called slugging process and wet granulating process. Both these processes possess many disadvantages and leave much to be desired.
In accordance with the slugging process, the various ingredients, in intimately admixed powder form, are subjected to high pressures to produce large slugs of the material as a cohered solid mass. These slugs are then milled into granules of the desired size and configuration, the granules being thereafter recompressed in the conventional tablet-forming equipment to produce the finished product. The slugging process is generally employed where the tablet ingredients may not be wetted due to some incompatibility or where they are heatsensitive and unstable. It is an expensive process which involves considerable labor and equipment and its application is limited and not always satisfactory.
The more common method is the wet granulating process. In accordance with this process, the ingredients which enter into the tablet are wetted down. The wetting agent generally consists of water, alcohol or other organic solvent with or without water, gum or other binder solutions, for example, acacia, tragacanth, methyl cellulose, gelatin, gelatinized starch, etc. The tablet ingredients, wetted as above, to the proper consistency are placed in a suitable drying oven. The dried solid cohered mass is then milled into granules of the required size, admixed with a suitable lubricant and formed into tablets as in the case of the slugging process. The wet granulating process is likewise expensive, requiring considerable labor. Moreover, where organic solvents are employed, these are evaporated and seldom recovered, thus adding to the production costs. The Wet granulating process cannot be used when the tablet ingredients are incompatible to wetting or are heat-sensitive.
It is thus a principal object of the present invention to provide an improved molding process.
Another object of the present invention is to provide an improved process for the manufacture of pills, tablets and the like.
Still another object of the present invention is to provide an improved method of producing pharmaceutical pills, tablets and the like.
A further object of the present invention is to provide an improved tablet producing method characterized by the absence of any slugging or wetting steps.
Still a further object of the present invention is to provide an improved tablet producing method which may be employed with materials sensitive to heat and wetting.
Another object of the present invention is to provide an improved inexpensive and versatile tablet producing process characterized by its low labor, material and equipment requirements and the use of standard apparatus. Following the general method contemplated by the present invention, a pharmaceutical pill, tablet or the like, is produced by admixing a physiologically active ingredient in a finely divided state with a molten, preferably water soluble binder, solidifying the resultant mixture, comminuting the solidified mixture into granules and form: ing said granules into tablets.
In accordance with a preferred embodiment of the improved method, the active ingredients and any desired excipients, such as powdered sugar, milk sugar, starch, etc. in a powdered intimately admixed state, are placed in a conventional mixer such as a pony mixer, change. can mixer, tumbler mixer, or any other suitable mixer. The mixer is actuated and the molten binder is slowly added during the continued mixing at a rate to efiect.
the formation of small balls or nodules. Upon cooling of the balls or nodules, a suitable lubricant such as talc,- magnesium stearate, stearic acid or dry starch is added; For example, 2% to 3% magnesium stearate and 4%; to 1% talc based on the final weight of the tablets may be advantageously employed. The balls or nodules are preferably of the order of about /a inch in diameter and, in any event, larger than about a 20 mesh. The balls or nodules together with the lubricant are then granulated in any well known fashion, such as by means of a Fitzpatrick comminuter, to produce granules of between 20 to 60 mesh depending upon the size of the tablet to be produced. The granules are then formed into :tablets in the usual manner.
The binding material employed in forming the granules, should preferably be Water soluble and should have a low melting point compatible with the other ingredients entering into the tablet so as not to adversely affect or decompose these ingredients and the melting point should not be too high for convenient handling. Binders having melting points below 120 C. are generally satisfactory, although this temperature may vary depending upon the other constituents. It is also preferable that the binder be colorless or white and not char or otherwise become discolored upon melting. Sorbitol has been found to excellently serve the function of the binder. It has a melting point of C. and is of a syrupy consistency or viscosity. Most satisfactory results have been obtained when the binder is from 10% to 15% by weight of the final mixture and is added to the other ingredients during the mixing or tumbling thereof at a rate preferably not exceeding 20 percent of the molten binder per minute, for example, 10 percent per minute.
An example of the present improved process is in the production of phenobarbital tablets having a running weight of 1.3 grains and each containing gram phenobarbital. The ingredients and quantities employed in the production of 1,050,000 of these tablets are as follows:
constituents may be varied approximately 10%.
In forming the tablets, the'phenobarbital powder, pow
'dered sugar, milk sugar slowly added to the agitated mixture over a period of approximately 10 minutes, the ingredients balling up in:
small roughly spherical nodules of about Ms inch diameter. The spherical nodules'are permitted to cool and solidify and the magnesium stearate, talc and dried starch added and uniformly distributed throughout the mass. The batch of lubricated nodules are then passed through a properly adjusted Fitzpatrick comminuter where the nodules are broken in granules of about 30 mesh. These granules are then formed into tablets in the usual and conventional manner.
While there have been described and illustrated preferred embodiments of the present invention, it is apparent that numerous alterations and omissions may be made without departing from the spirit thereof.
I claim:
1. The improved method of producing pills comprising the steps of slowly adding molten sorbitol to a finely divided active ingredient while agitating said active ingredient to produce nodules of the order of approximately diameter of said sorbitol and said active ingredient,
cooling and solidifying said nodules, comminuting said nodules to produce granules of between approximately 20 and 60 mesh and compressing said granules into said tablets, wherein the sorbitol constitutes between approximately 10% and 15% by weight of the product.
4 2. The improved method in accordance with claim 1, wherein said active ingredient is admixed with excipients in a finely divided state prior to the addition of said molten sorbitol.
5 3. The improved method in accordance with claim 1, including the step of adding a lubricant to said solidified nodules prior to comminution thereof.
4. The improved methodin accordance with claim 1, wherein said molten sorbitol is added to said active in- 10 gredient at a rate not exceeding approximately 20% of the molten binder per minute.
References Cited in the file of this patent 15 UNITED STATES PATENTS 2,807,559 Steiner Sept. 24, 1957 FOREIGN PATENTS 514,047 Great Britain Oct. 30, 1939 20 OTHER REFERENCES

Claims (1)

1. THE IMPROVED METHOD OF PRODUCING PILLS COMPRISING THE STEPS OF SLOWLY ADDING MOLTEN SORBITOL TO A FINELY DIVIDED ACTIVE INGREDIENT WHILE AGITATING SAID ACTIVE INGREDIENT TO PRODUCE NODULES OF THE ORDER OF APPROXIMATELY 1/8" DIAMETER OF SAID SORBITOL AND SAID ACTIVE INGREDIENT COOLING AND SOLIDIFYING SAID NODULES, COMMINUTING SAID NODULES TO PRODUCE GRANULES OF BETWEEN APPROXIMATELY 20 AND 60 MESH AND COMPRESSING SAID GRANULES INTO SAID TABLETS, WHEREIN THE SORBITOL CONSTITUTES BETWEEN APPROXIMATELY 10% AND 15% BY WEIGHT OF THE PRODUCT.
US556416A 1955-12-30 1955-12-30 Tablet molding process Expired - Lifetime US2878160A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US556416A US2878160A (en) 1955-12-30 1955-12-30 Tablet molding process

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US556416A US2878160A (en) 1955-12-30 1955-12-30 Tablet molding process

Publications (1)

Publication Number Publication Date
US2878160A true US2878160A (en) 1959-03-17

Family

ID=24221254

Family Applications (1)

Application Number Title Priority Date Filing Date
US556416A Expired - Lifetime US2878160A (en) 1955-12-30 1955-12-30 Tablet molding process

Country Status (1)

Country Link
US (1) US2878160A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3048464A (en) * 1959-04-07 1962-08-07 Carl E Fisher Water soluble dye form and method of making
US3200039A (en) * 1962-05-28 1965-08-10 Pfizer & Co C Non-granulated tablets with 20% sorbitol in a particle size of from about 100mu to about 2000mu
US3398225A (en) * 1964-11-02 1968-08-20 Shell Oil Co Coated 2, 2-dichlorovinyl phosphate and polyvinyl chloride resin anthelmintic compositions
US3428728A (en) * 1965-10-21 1969-02-18 Hans Lowey Timed release sublingual medications

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB514047A (en) * 1938-03-25 1939-10-30 Ernest Edmund Wells Improvements in and relating to processes for manufacturing insulated products in the form of powder
US2807559A (en) * 1954-12-29 1957-09-24 Helen J Steiner Cube sugar process and product

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB514047A (en) * 1938-03-25 1939-10-30 Ernest Edmund Wells Improvements in and relating to processes for manufacturing insulated products in the form of powder
US2807559A (en) * 1954-12-29 1957-09-24 Helen J Steiner Cube sugar process and product

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3048464A (en) * 1959-04-07 1962-08-07 Carl E Fisher Water soluble dye form and method of making
US3200039A (en) * 1962-05-28 1965-08-10 Pfizer & Co C Non-granulated tablets with 20% sorbitol in a particle size of from about 100mu to about 2000mu
US3398225A (en) * 1964-11-02 1968-08-20 Shell Oil Co Coated 2, 2-dichlorovinyl phosphate and polyvinyl chloride resin anthelmintic compositions
US3428728A (en) * 1965-10-21 1969-02-18 Hans Lowey Timed release sublingual medications

Similar Documents

Publication Publication Date Title
US3147187A (en) Sustained release pharmaceutical
US3965256A (en) Slow release pharmaceutical compositions
US2540253A (en) Granulation process
US4693750A (en) Direct tabletting agent
US3279998A (en) Method of preparing sustained release tablets
JP2697754B2 (en) Pharmaceutical pancreatin micropellet particles, method for preparing the particles, gastric juice-resistant coated pancreatin micropellets for pharmaceutical, and method for manufacturing the micropellets
US3062720A (en) Sustained release pharmaceutical tablet
US4235870A (en) Slow release pharmaceutical compositions
US3134719A (en) Calcium phosphates in tablet compressing
US2985562A (en) Effervescent compositions
JPS6140204B2 (en)
US3078216A (en) Prolonged release oral pharmaceutical preparations
US3200039A (en) Non-granulated tablets with 20% sorbitol in a particle size of from about 100mu to about 2000mu
US2980589A (en) Process for producing anhydrous granulation of a medicinally active waterlabile powder
US4203997A (en) Directly-pressable ascorbic acid-containing granulates
US4151274A (en) Process and composition for the production of suppositories
US3121663A (en) Carbon dioxide releasing laxative suppository
US2820741A (en) Aluminum aspirin granulation and method for making
US3836618A (en) Process for the uniform distribution of a drug on a granulated base
US3136695A (en) Anhydrous thixotropic gel sustained release therapeutic compositions and method of preparation
US3039933A (en) Ethyl cellulose-polyethylene glycol tablet matrix
US2878160A (en) Tablet molding process
US2857313A (en) Self-lubricating granulation
US3084104A (en) Process of preparing granulation of medicinal agents
US3857933A (en) Process for the manufacture of a drug dosage form permitting controlled release of active ingredient